|
 |
 |
 |
EXPO 2015 "NUTRIRE IL PIANETA, ENERGIA PER LA VITA"
TORNA ALL'ELENCO DEI CONTRIBUTI
PETIZIONE SU EXPO 2015
Se vuoi lasciare il tuo commento, segnalazione o suggerimento su questa iniziativa...
Pagina: <Precedente ... 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 ... Successivo>
Alphonso il giorno 10/03/2021 ha scritto:
Где ÑÐµÐ³Ð¾Ð´Ð½Ñ Ð¼Ð¾Ð¶Ð½Ð¾ поÑмотреть порно беÑплатно? Многие задаютÑÑ Ð´Ð°Ð½Ð½Ñ‹Ð¼ вопроÑом, не проверив данный Ñайт: порно Ведь только здеÑÑŒ предоÑтавлÑÑŽÑ‚ к проÑмотру лучшее порно Рунета, Ñовершенно без оплат и подпиÑок. ПриÑоединÑйÑÑ Ð¸ Ñмотри топ порно беÑплатно уже ÑегоднÑ!
DanielGal il giorno 26/09/2021 ha scritto:
The compounding of nivolumab and ipilimumab maintained its survival dominance upwards chemotherapy with at least 3 years of backup to each patients with unresectable malign pleural mesothelioma, according to CheckMate 743 measured over results.
Researchers observed the good of the first-line immunotherapy regimen in defiance of patients having been off one's rocker remedial definition after nearly 1 year. The findings, presented during the productive ESMO Congress, also showed no changed refuge signals with nivolumab (Opdivo, Bristol Myers Squibb) head start ipilimumab (Yervoy, Bristol Myers Squibb).
Matter derived from Peters S, et al. Pr‚cis LBA65. Presented at: European Sodality good of Medical Oncology Congress (main converging); Sept. 17-21, 2021.
“Mesothelioma has historically been an damned difficult?to?treat cancer, as it forms in the lining of the lungs less than as a fix aside tumor. It is also an disdainful cancer with defective forecast and 5?year survival rates of there 10%,” Solange Peters, MD, PhD, of the medical oncology services and directorship of thoracic oncology at Lausanne University Salubrity nave in Switzerland, told Healio. “At the the approval of nivolumab annexe ipilimumab, no single systemic treatment options that could specifics survival inasmuch as patients with this acid cancer had been in influence inasmuch as more than 15 years.”
The randomized younger 3 CheckMate 743 experience included 605 patients with untreated pernicious pleural mesothelioma, stratified according to making love and histology (epithelioid vs. non-epithelioid).
Researchers randomly assigned 303 patients to 3 mg/kg nivolumab, a PD-1 inhibitor, every 2 weeks and 1 mg/kg ipilimumab, which targets CTLA-4, every 6 weeks in the mechanic of up to 2 years. The other 302 patients received platinum-based doublet chemotherapy with 75 mg/m2 cisplatin or carboplatin area underneath the curve 5 asset 500 mg/m2 pemetrexed on
Joness#g11ennick[Yjnylobhowvokiho,2,5] il giorno 24/09/2021 ha scritto:
Great
COMMENTA GLI ALTRI CONTRIBUTI
|
|
|
|
|